Lantern Pharma Stock Forum

$Lantern Pharma (LTRN.US)$
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Monday, 9th December at 8:15 am
Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits.
Expansion into Taiwan is particularly significant as over 50% of lung cancer cases in Taiwan occur in never-smokers.
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence...

$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
5 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE

$Lantern Pharma (LTRN.US)$
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Tuesday, 3rd December at 8:00 am
• This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
• Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...

$Lantern Pharma (LTRN.US)$
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...

$Lantern Pharma (LTRN.US)$ Reuters· 2 mins ago
Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality

$Lantern Pharma (LTRN.US)$ Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients

$China Pharma (CPHI.US)$ $Bright Minds Biosciences (DRUG.US)$ $Lantern Pharma (LTRN.US)$ $Cytosorbents (CTSO.US)$ $Intensity Therapeutics (INTS.US)$ $Multi Ways (MWG.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $X3 Holdings (XTKG.US)$ $Protagenic Therapeutics (PTIX.US)$ $GRI Bio (GRI.US)$ $Paranovus Entertainment Technology (PAVS.US)$ $VSee Health (VSEE.US)$
📊⚡️📊

$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE